文献速递抗栓抗凝管理药物相互作用

房颤患者经皮冠状动脉介入治疗后的抗栓治疗:三重困境

Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble.
PubMed 文献 · Drugs · 2018-01-01

本文综述房颤患者经皮冠状动脉介入治疗后抗栓策略的困境,即双联抗血小板治疗与口服抗凝药均必要但增加出血风险。当前证据支持在采用现代药物洗脱支架时,双联治疗(口服抗凝药+一种抗血小板药)的净临床获益,建议避免常规使用三联治疗,优先选择非维生素K拮抗剂口服抗凝药。

要点

  • 三联治疗患者缺血与出血风险均高,需个体化制定二级预防策略。
  • 现代药物洗脱支架时代,双联治疗较三联治疗显著降低出血风险。
  • 非临床试验中应避免常规全剂量三联治疗,优先选用非维生素K拮抗剂口服抗凝药。

核心结论

  • 在采用现代药物洗脱支架的经皮冠状动脉介入治疗策略时,双联治疗的净临床获益应使心内科医生有信心停用阿司匹林。
  • 在非临床试验患者中,应避免常规使用全剂量口服三联治疗(双联抗血小板药+全剂量抗凝)。
  • 非维生素K拮抗剂口服抗凝药可视为房颤患者经皮冠状动脉介入治疗后额外的避免出血策略。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • 双联治疗较三联治疗显著降低出血风险,且主要试验间结果一致。
  • 非维生素K拮抗剂口服抗凝药和新型药物洗脱支架均提高了感知和实际安全性。

临床怎么用

  • 对房颤经皮冠状动脉介入治疗后患者,采用现代药物洗脱支架时可考虑双联治疗并停用阿司匹林。
  • 避免常规全剂量三联治疗,优先选择非维生素K拮抗剂口服抗凝药作为抗凝成分。

局限性

  • 需等待更多随机试验和荟萃分析证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One of the most common conundrums in all cardiovascular medicine pertains to the care of patients with atrial fibrillation after percutaneous coronary intervention, because of both dual antiplatelet therapy and oral anticoagulant therapy would seem to be necessary to reduce risks of stent thrombosis and thromboembolism, respectively, but also with an inevitable trade-off of more bleeding. Patients who require triple therapy are at high risk of both ischaemia and bleeding; therefore, defining a personalised secondary prevention strategy aimed at achieving the best net clinical benefit is essential. The good news is that we have entered an era of increased perceived and tangible safety that applies to both non-vitamin K-antagonist oral anticoagulants and newer drug-eluting stents. Even if the consistency across the major trials and the significantly lower risk of bleeding with dual therapy make it hard to argue that triple therapy should be used routinely, the aggregate evidence suggests that the net clinical benefit of dual therapy should give cardiologists confidence to drop aspirin when they are using a contemporary percutaneous coronary intervention strategy with drug-eluting stents. Waiting for more randomised trials and meta-analyses, for the time being, in patients not in clinical trials, full-dose oral triple therapy with dual antiplatelet agents and full-dose anticoagulation should be avoided as a routine practice, and the choice of the proper, that is, safer, oral anticoagulant, namely a non-vitamin K-antagonist oral anticoagulant, may be regarded by now as an additional bleeding avoiding strategy in patients with atrial fibrillation undergoing percutaneous coronary intervention.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Leggio M, Fusco A, Severi P, et al. Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble. Drugs. 2018. PMID: 30132258. doi:10.1007/s40265-018-0957-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。